drugset / Trial / NCT03415854
Paclitaxel Protein Bound Plus Cisplatin Plus Gemcitabine and Paricalcitol for Pancreatic Adenocarcinoma (NABPLAGEMD)
Phase 2
Completed
34 enrolled
HonorHealth Research Institute
Abramson Cancer Center at Penn Medicine · collabBarts Cancer Institute · collabCancer Research UK · collabImaging Endpoints · collabLustgarten Foundation · collabMayo Clinic · collabPrinceton University · collabSalk Institute for Biological Studies · collabStand Up To Cancer · collabTranslational Genomics Research Institute · collabUniversity of California, San Diego · collab
NaSingle-groupOpen-labelTreatment
Summary
The purpose of this study is to determine if the combination of paclitaxel protein bound, gemcitabine, cisplatin, paricalcitol are effective in individuals with previously untreated metastatic pancreatic cancer.
Timeline
- Start
- 2018-01-31
- Primary completion
- 2023-12-11
- Completion
- 2023-12-11
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Cisplatin | Other / unclassified | — | — |
| Subject | Gemcitabine | Small molecule | — | — |
| Subject | Paclitaxel | Small molecule | — | — |
| Subject | Paricalcitol | Other / unclassified | — | — |